PGN-EDODM1 is under clinical development by Pepgen and currently in Phase I for Myotonic Dystrophy. According to GlobalData, Phase I drugs for Myotonic Dystrophy does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the PGN-EDODM1 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PGN-EDODM1 overview
PGN-EDODM1 is under development for the treatment of myotonic dystrophy type 1 (DM1). It is administered through intravenous route. The therapeutic candidate is a phosphorodiamidate morpholino oligonucleotide (PMO) and is being developed based on enhanced delivery oligonucleotide (EDO) platform. It acts by targeting myotonic dystrophy protein kinase (DMPK).
Pepgen overview
Pepgen (Pepgen) is a clinical-stage biotechnology company. It focuses on next generation of oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases. The company Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptide conjugates for oligonucleotide cargo therapeutics. This pesticides also transports oligonucleotides into target tissues, including smooth, skeletal and cardiac muscle, and the CNS. The company also treats neuromuscular diseases like Duchenne muscular dystrophy (DMD), and myotonic dystrophy type 1 (DM1) and are not efficiently taken up into these cells. It also works in partnerships with pharmaceutical companies to develop therapeutics focusing on neuromuscular diseases. Pepgen is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of PGN-EDODM1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
